| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| cytarabine | Injection, solution | 100 mg | Resolved | Available | Unexpected increase in consumer demand | 10/01/2025 |
| topiramate | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 10/01/2025 |
| topiramate | Tablet, film coated | 200 mg | Resolved | Available | Manufacturing | 10/01/2025 |
| levetiracetam | Tablet, film coated | 500 mg | Resolved | Available | Manufacturing | 10/01/2025 |
| clonidine hydrochloride | Tablet, uncoated | 100 microgram | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 10/01/2025 |
| bisoprolol fumarate | Tablet | 2.5 mg | Resolved | Available | Manufacturing | 10/01/2025 |
| azithromycin dihydrate | Tablet, film coated | 524.05 mg | Current | Unavailable | Manufacturing | 10/01/2025 |
| eftrenonacog alfa | Injection, powder for | 1000 IU | Resolved | Available | Unexpected increase in consumer demand | 10/01/2025 |
| eftrenonacog alfa | Injection, powder for | 250 IU | Current | Unavailable | Unexpected increase in consumer demand | 10/01/2025 |
| clopidogrel besilate | Tablet, film coated | 112.1 mg | Current | Limited Availability | Manufacturing | 10/01/2025 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Unavailable | Unexpected increase in consumer demand | 10/01/2025 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Unavailable | Manufacturing | 10/01/2025 |
| irbesartan | Tablet, film coated | 300 mg | Resolved | Available | Manufacturing | 10/01/2025 |
| ivabradine hydrochloride | Tablet, film coated | 8.085 mg | Anticipated | Available | Manufacturing | 10/01/2025 |
| mesalazine | Tablet, enteric coated | 250 mg | Current | Limited Availability | Manufacturing | 10/01/2025 |
| risperidone | Tablet, film coated | .5 mg | Resolved | Available | Manufacturing | 10/01/2025 |
| ravulizumab | Injection, intravenous infusion | 100 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 10/01/2025 |
| prucalopride succinate | Tablet | 2.642 mg | Current | Unavailable | Manufacturing | 10/01/2025 |
| thiotepa | Injection, powder for | 15 mg | Resolved | Available | Unexpected increase in consumer demand | 10/01/2025 |
| thiotepa | Injection, powder for | 15 mg | Current | Unavailable | Commercial Changes / Commercial viability | 10/01/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | 1.54 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 10/01/2025 |
| doxycycline hyclate | Tablet, film coated | 57.5 mg | Current | Limited Availability | Manufacturing | 10/01/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | .77 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 10/01/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 10/01/2025 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 10/01/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 10/01/2025 |
| clonidine hydrochloride | Tablet, uncoated | 150 microgram | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 10/01/2025 |
| famotidine | Tablet, film coated | 20 mg | Current | Unavailable | Manufacturing | 10/01/2025 |
| famotidine | Tablet, film coated | 40 mg | Current | Unavailable | Manufacturing | 10/01/2025 |
| nizatidine | Capsule, hard | 300 mg | Current | Limited Availability | Manufacturing | 10/01/2025 |
| dopamine hydrochloride | Injection, concentrated | 40 mg/mL | Resolved | Available | Manufacturing | 9/01/2025 |
| paroxetine hydrochloride | Tablet, film coated | 22.21 mg | Current | Limited Availability | Manufacturing | 9/01/2025 |
| mesalazine | Tablet, enteric coated | 800 mg | Current | Limited Availability | Manufacturing | 9/01/2025 |
| Trastuzumab | Injection, powder for | 60 mg | Current | Unavailable | Manufacturing | 9/01/2025 |
| naloxone hydrochloride dihydrate | Spray, nasal | 2.2 mg/actuation | Current | Limited Availability | Manufacturing | 9/01/2025 |
| daptomycin | Injection, powder for | 500 mg | Resolved | Available | Manufacturing | 9/01/2025 |
| Adalimumab | Injection, solution | 40 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 9/01/2025 |
| carbamazepine | Tablet, modified release | 200 mg | Resolved | Available | Manufacturing | 9/01/2025 |
| oxcarbazepine | Tablet, film coated | 150 mg | Resolved | Available | Manufacturing | 9/01/2025 |
| citalopram hydrobromide | Tablet, film coated | 24.98 mg | Current | Limited Availability | Manufacturing | 9/01/2025 |
| Meningococcal polysaccharide group C~Tetanus toxoid | Injection, suspension | 20 microgram/mL~20 microgram/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 9/01/2025 |
| diclofenac sodium | Suppository, moulded | 50 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 9/01/2025 |
| sevelamer hydrochloride | Tablet, film coated | 800 mg | Resolved | Available | Manufacturing | 8/01/2025 |
| hydrocortisone acetate | Eye Ointment | 10 mg/g | Current | Unavailable | Manufacturing | 8/01/2025 |
| tamsulosin hydrochloride~dutasteride | Capsule, modified release | 400 microgram~500 microgram | Resolved | Available | Manufacturing | 8/01/2025 |
| rosuvastatin calcium~ezetimibe | Tablet~Tablet, film coated | 20.791 mg~10 mg | Resolved | Available | Manufacturing | 8/01/2025 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Current | Limited Availability | Manufacturing | 8/01/2025 |
| efmoroctocog alfa | Injection, powder for | 2000 IU | Current | Unavailable | Unexpected increase in consumer demand | 8/01/2025 |
| cisatracurium besilate | Injection, solution | 14.07 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 8/01/2025 |
| citalopram hydrobromide | Tablet, film coated | 12.495 mg | Current | Unavailable | Manufacturing | 8/01/2025 |
| buprenorphine | Drug delivery system, transdermal | 5 mg | Current | Limited Availability | Manufacturing | 8/01/2025 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 8/01/2025 |
| olmesartan medoxomil~hydrochlorothiazide | Tablet | 20 mg~12.5 mg | Current | Unavailable | Manufacturing | 8/01/2025 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet | 25 mg~40 mg | Current | Limited Availability | Manufacturing | 8/01/2025 |
| Trastuzumab | Injection, powder for | 150 mg | Current | Unavailable | Manufacturing | 8/01/2025 |
| clobazam | Tablet, uncoated | 10 mg | Current | Unavailable | Manufacturing | 8/01/2025 |
| oxaliplatin | Injection, concentrated | 100 mg | Current | Limited Availability | Manufacturing | 8/01/2025 |
| reboxetine mesilate | Tablet, uncoated | 5.224 mg | Anticipated | Available | Manufacturing | 8/01/2025 |
| ethosuximide | Capsule, soft | 250 mg | Discontinued | Unavailable | Manufacturing | 8/01/2025 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Unavailable | Manufacturing | 7/01/2025 |
| fentanyl | Drug delivery system, transdermal | 2.1 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 7/01/2025 |
| tramadol hydrochloride | Tablet, modified release | 200 mg | Current | Limited Availability | Manufacturing | 7/01/2025 |
| bisoprolol fumarate | Tablet | 5 mg | Resolved | Available | Manufacturing | 7/01/2025 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Limited Availability | Manufacturing | 7/01/2025 |
| bortezomib | Injection, powder for | 3.5 mg | Current | Limited Availability | Manufacturing | 7/01/2025 |
| amlodipine besilate | Tablet | 6.93 mg | Current | Limited Availability | Manufacturing | 7/01/2025 |
| doxylamine succinate~codeine phosphate hemihydrate~paracetamol | Tablet, uncoated | 5.1 mg~10 mg~500 mg | Resolved | Available | Manufacturing | 7/01/2025 |
| cefuroxime axetil | Tablet, film coated | 300.715 mg | Current | Limited Availability | Manufacturing | 7/01/2025 |
| ezetimibe | Tablet | 10 mg | Resolved | Available | Unexpected increase in consumer demand | 7/01/2025 |
| tadalafil | Tablet, film coated | 5 mg | Resolved | Available | Manufacturing | 7/01/2025 |
| tadalafil | Tablet, film coated | 20 mg | Resolved | Available | Manufacturing | 7/01/2025 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.935 mg~40 mg | Current | Unavailable | Manufacturing | 7/01/2025 |
| dexmedetomidine hydrochloride | Injection, concentrated | 118 microgram/mL | Resolved | Available | Manufacturing | 7/01/2025 |
| dimethyl fumarate | Capsule, enteric | 120 mg | Current | Limited Availability | Manufacturing | 7/01/2025 |
| metoprolol succinate | Tablet, modified release | 23.75 mg | Current | Limited Availability | Manufacturing | 7/01/2025 |
| lanreotide acetate | Injection, solution | 133.33 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 7/01/2025 |
| lanreotide acetate | Injection, solution | 100 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 7/01/2025 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 109 mg | Current | Unavailable | Manufacturing | 7/01/2025 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 54.5 mg | Current | Unavailable | Manufacturing | 7/01/2025 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 27.25 mg | Current | Unavailable | Manufacturing | 7/01/2025 |
| paracetamol | Tablet, modified release | 665 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 7/01/2025 |
| heparin sodium | Injection, solution | 5000 IU/mL | Resolved | Available | Manufacturing | 7/01/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Resolved | Available | Manufacturing | 7/01/2025 |
| gabapentin | Tablet, film coated | 800 mg | Current | Unavailable | Manufacturing | 6/01/2025 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Resolved | Available | Manufacturing | 6/01/2025 |
| quetiapine fumarate | Tablet, film coated | 345.36 mg | Resolved | Available | Manufacturing | 6/01/2025 |
| adefovir dipivoxil | Tablet | 10 mg | Resolved | Available | Unexpected increase in consumer demand | 6/01/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 6/01/2025 |
| apomorphine hydrochloride hemihydrate | Injection, solution | 10 mg | Resolved | Available | Manufacturing | 6/01/2025 |
| lurasidone hydrochloride | Tablet, film coated | 80 mg | Current | Unavailable | Manufacturing | 6/01/2025 |
| furosemide | Injection, solution | 10 mg/mL | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 6/01/2025 |
| rosuvastatin calcium~ezetimibe | Tablet | 10.4 mg~10 mg | Current | Unavailable | Manufacturing | 6/01/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.6 mg | Current | Unavailable | Manufacturing | 6/01/2025 |
| tamoxifen citrate | Tablet, uncoated | 30.4 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 6/01/2025 |
| cabergoline | Tablet, uncoated | 1 mg | Anticipated | Available | Manufacturing | 6/01/2025 |
2025年1月13日